AU722985B2 - Compounds and methods for modulating cell adhesion - Google Patents

Compounds and methods for modulating cell adhesion Download PDF

Info

Publication number
AU722985B2
AU722985B2 AU33322/97A AU3332297A AU722985B2 AU 722985 B2 AU722985 B2 AU 722985B2 AU 33322/97 A AU33322/97 A AU 33322/97A AU 3332297 A AU3332297 A AU 3332297A AU 722985 B2 AU722985 B2 AU 722985B2
Authority
AU
Australia
Prior art keywords
cyclic peptide
cadherin
mammal
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33322/97A
Other languages
English (en)
Other versions
AU3332297A (en
Inventor
Orest W. Blaschuk
Barbara Joan Gour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Publication of AU3332297A publication Critical patent/AU3332297A/en
Application granted granted Critical
Publication of AU722985B2 publication Critical patent/AU722985B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU33322/97A 1996-07-12 1997-07-11 Compounds and methods for modulating cell adhesion Ceased AU722985B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2161296P 1996-07-12 1996-07-12
US60/021612 1996-07-12
PCT/CA1997/000489 WO1998002452A2 (en) 1996-07-12 1997-07-11 Compounds and methods for modulating cell adhesion

Publications (2)

Publication Number Publication Date
AU3332297A AU3332297A (en) 1998-02-09
AU722985B2 true AU722985B2 (en) 2000-08-17

Family

ID=21805187

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33322/97A Ceased AU722985B2 (en) 1996-07-12 1997-07-11 Compounds and methods for modulating cell adhesion

Country Status (8)

Country Link
US (3) US6031072A (enExample)
EP (1) EP0937103B1 (enExample)
JP (1) JP2001500475A (enExample)
AU (1) AU722985B2 (enExample)
CA (1) CA2259966A1 (enExample)
DE (1) DE69738326T2 (enExample)
ES (1) ES2297861T3 (enExample)
WO (1) WO1998002452A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417325B1 (en) 1996-07-12 2002-07-09 Mcgill University Compounds and methods for cancer therapy
US6169071B1 (en) * 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6610821B1 (en) 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
AU722985B2 (en) 1996-07-12 2000-08-17 Mcgill University Compounds and methods for modulating cell adhesion
US6465427B1 (en) 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
US6333307B1 (en) 1996-07-12 2001-12-25 Mcgill University Compounds and method for modulating neurite outgrowth
US6562786B1 (en) 1996-07-12 2003-05-13 Mcgill University Compounds and methods for modulating apoptosis
US6207639B1 (en) 1996-07-12 2001-03-27 Mcgill University Compounds and methods for modulating neurite outgrowth
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US20020168761A1 (en) * 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6346512B1 (en) 1996-07-12 2002-02-12 Mcgill University Compounds and methods for modulating cell adhesion
US7122623B2 (en) * 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
US6551994B1 (en) * 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6472367B1 (en) 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
US20050203025A1 (en) * 1998-05-05 2005-09-15 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US6680175B2 (en) 1998-05-05 2004-01-20 Adherex Technologies, Inc. Methods for diagnosing and evaluating cancer
US7481999B2 (en) * 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
AU759144B2 (en) * 1998-05-05 2003-04-03 Adherex Technologies Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
CA2337794A1 (en) 1998-07-02 2000-01-13 Jennifer D. Tousignant Transgene expression in polarized cells
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
WO2000062815A2 (en) * 1999-04-15 2000-10-26 Glaxo Group Limited Novel pharmaceutical composition suitable for gene therapy
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
US20040254099A1 (en) * 1999-04-21 2004-12-16 Adherex Technologies, Inc. Compounds and methods for modulating beta-catenin mediated gene expression
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
AU2002226075A1 (en) * 2000-10-23 2002-05-06 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
US20030105025A1 (en) * 2001-10-31 2003-06-05 Fortuna Haviv Tri-and tetrapeptides having antiangiogenic activity
US7175990B2 (en) * 2002-02-26 2007-02-13 The Regents Of The University Of California Method of determining endometrial receptivity
AU2003298475A1 (en) 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
WO2004044000A2 (en) * 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
US7196061B2 (en) 2003-09-10 2007-03-27 Wyeth Compounds that modulate neuronal growth and their uses
WO2005039506A2 (en) * 2003-10-24 2005-05-06 Exelixis, Inc. P70s6 kinase modulators and method of use
WO2005097112A2 (en) * 2004-03-08 2005-10-20 Wyeth Ion channel modulators
US7169756B2 (en) * 2004-04-16 2007-01-30 Mcmaster University Streptogramin antibiotics
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
US20110034396A1 (en) * 2005-09-28 2011-02-10 Biovascular, Inc. Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
EP2023735A4 (en) * 2006-05-15 2011-05-25 Biogen Idec Inc USE OF ANTAGONISTS OF THE NOGO RECEPTOR 1 (NGR1) TO PROMOTE THE SURVIVAL OF OLIGODENDROCYTES
US20080194467A1 (en) * 2006-09-27 2008-08-14 Adherex Technologies, Inc. Cancer treatment methods using cadherin antagonists in combination with anticancer agents
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
US20090291967A1 (en) * 2008-03-05 2009-11-26 Adherex Technologies, Inc. Small molecule modulators of cell adhesion
US9599603B2 (en) * 2008-07-16 2017-03-21 Case Western Reserve University Methods and compositions for modulating adhesion and migration of cadherin expressing cells
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
US8680150B2 (en) 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
AU2010298338A1 (en) * 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
FR2980741B1 (fr) 2011-09-30 2014-03-14 Saint Gobain Procede d'assemblage par collage d'un vitrage sur un support avec interposition d'une cale d'ecartement, vitrage muni d'une cale d'ecartement, cale, cordon profile et ensemble de cales.
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
JP2016520592A (ja) 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
US9133241B2 (en) 2013-10-11 2015-09-15 Tarix Pharmaceuticals Ltd. Peptide compositions
RU2016112931A (ru) 2013-10-11 2017-11-16 Терикс Фармасьютикалз Лтд. Композиции новых пептидов
JP2017501133A (ja) 2013-11-25 2017-01-12 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ Ｃｘｃｒ拮抗性ペプチド及びその用途
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US9884921B2 (en) 2014-07-01 2018-02-06 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
WO2016100301A1 (en) 2014-12-15 2016-06-23 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
GB2538947A (en) * 2014-12-19 2016-12-07 Neuro-Bio Ltd Cancer
WO2016097753A1 (en) * 2014-12-19 2016-06-23 Neuro-Bio Ltd Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
MA43230A (fr) 2015-10-14 2021-04-14 Tarix Pharmaceuticals Ltd Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
KR102167755B1 (ko) * 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
EP3986439A4 (en) * 2019-06-21 2023-10-04 University of Kansas COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF BRAIN DISEASES
WO2021183863A1 (en) 2020-03-13 2021-09-16 Constant Therapeutics Llc Methods and compositions for treatment of coronavirus infection
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN116535406B (zh) * 2022-01-25 2025-06-24 中国科学院大连化学物理研究所 一种多萜衍生物的对映选择性合成方法及多萜衍生物
CN116535281B (zh) * 2022-01-25 2025-06-24 中国科学院大连化学物理研究所 一种手性环状单萜衍生物及其合成方法
WO2025122594A1 (en) 2023-12-04 2025-06-12 Constant Therapeutics, Llc Improved methods and compositions for the treatment of pemphigus or pemphigoid disease
WO2025137668A1 (en) 2023-12-21 2025-06-26 Constant Therapeutics, Llc Methods and compositions for the treatment of optic neuropathy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079600A (en) * 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5231082A (en) * 1989-05-10 1993-07-27 Monsanto Company Cyclic peptide with anti-metastasis activity
CA2067183A1 (en) * 1989-09-27 1991-03-28 Lee L. Rubin Compositions for cell adhesion inhibition and methods of use
EP0619841B1 (en) * 1990-10-30 1998-07-08 La Jolla Cancer Research Foundation T-cadherin adhesion molecule
AU3141693A (en) * 1991-11-22 1993-06-15 Friedman, Mark M. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
US5646250A (en) 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
WO1994011401A1 (en) 1992-11-17 1994-05-26 Yale University Human homolog of the e-cadherin gene and methods based thereon
US5591432A (en) * 1993-02-17 1997-01-07 Becton, Dickinson And Company Antibody to the neural cell adhesion molecule and methods of use
US5665590A (en) * 1994-07-29 1997-09-09 Systemix, Inc. Method for isolating and directly cloning genes which encode cell-surface and secreted proteins
WO1996040781A1 (en) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
GB9517098D0 (en) * 1995-08-21 1995-10-25 Imperial College Receptor
AU722985B2 (en) 1996-07-12 2000-08-17 Mcgill University Compounds and methods for modulating cell adhesion
US6169071B1 (en) 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin

Also Published As

Publication number Publication date
DE69738326D1 (de) 2008-01-10
US6326352B1 (en) 2001-12-04
EP0937103A2 (en) 1999-08-25
DE69738326T2 (de) 2008-07-03
WO1998002452A3 (en) 1998-03-05
AU3332297A (en) 1998-02-09
US20020151475A1 (en) 2002-10-17
JP2001500475A (ja) 2001-01-16
WO1998002452A2 (en) 1998-01-22
US6031072A (en) 2000-02-29
CA2259966A1 (en) 1998-01-22
ES2297861T3 (es) 2008-05-01
US6914044B2 (en) 2005-07-05
EP0937103B1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
AU722985B2 (en) Compounds and methods for modulating cell adhesion
US6169071B1 (en) Compounds and methods for modulating cell adhesion
US6310177B1 (en) Compounds and methods for modulating tissue permeability
AU764271B2 (en) Compounds and methods for modulating cadherin-mediated functions
US7122623B2 (en) Compounds and methods for modulating cell adhesion
AU773028B2 (en) Compounds and methods for modulating claudin-mediated functions
US6465427B1 (en) Compounds and methods for modulating cell adhesion
US6346512B1 (en) Compounds and methods for modulating cell adhesion
US6756356B2 (en) Compounds and methods for modulating claudin-mediated functions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)